BACKGROUND: Long chain 3-hydroxyacyl-CoA-dehydrogenase (LCHAD) is one of the enzymes involved in the breakdown of fatty acids. A deficiency of this enzyme is associated with life threatening episodes of hypoketotic hypoglycaemia during prolonged fasting. Neuropathy and retinopigmentary changes were mentioned in only a few cases. METHODS: The case histories of two girls, aged 8 and 15 years, with LCHAD deficiency are reported. RESULTS: Both children with LCHAD deficiency exhibited extensive macular pigmentary depositions and a 'salt and pepper' scattering of pigment in their retinas. The patients have decreasing visual acuity. CONCLUSION: The early recognition of LCHAD deficiency can increase the life expectancy in these patients through avoiding catabolism and through appropriate diets. Patients tend to be free of symptoms between attacks, however. Testing for the disorder, therefore, should be included in the diagnostic process for children with retinal dystrophy, in particular when other clinical symptoms are known to have occurred.
BACKGROUND:Long chain 3-hydroxyacyl-CoA-dehydrogenase (LCHAD) is one of the enzymes involved in the breakdown of fatty acids. A deficiency of this enzyme is associated with life threatening episodes of hypoketotic hypoglycaemia during prolonged fasting. Neuropathy and retinopigmentary changes were mentioned in only a few cases. METHODS: The case histories of two girls, aged 8 and 15 years, with LCHAD deficiency are reported. RESULTS: Both children with LCHAD deficiency exhibited extensive macular pigmentary depositions and a 'salt and pepper' scattering of pigment in their retinas. The patients have decreasing visual acuity. CONCLUSION: The early recognition of LCHAD deficiency can increase the life expectancy in these patients through avoiding catabolism and through appropriate diets. Patients tend to be free of symptoms between attacks, however. Testing for the disorder, therefore, should be included in the diagnostic process for children with retinal dystrophy, in particular when other clinical symptoms are known to have occurred.
Authors: C Dionisi Vici; A B Burlina; E Bertini; C Bachmann; M R Mazziotta; F Zacchello; G Sabetta; D E Hale Journal: J Pediatr Date: 1991-05 Impact factor: 4.406
Authors: R J Wanders; L IJlst; A H van Gennip; C Jakobs; J P de Jager; L Dorland; F J van Sprang; M Duran Journal: J Inherit Metab Dis Date: 1990 Impact factor: 4.982
Authors: R J Wanders; M Duran; L Ijlst; J P de Jager; A H van Gennip; C Jakobs; L Dorland; F J van Sprang Journal: Lancet Date: 1989-07-01 Impact factor: 79.321
Authors: M Duran; R J Wanders; J P de Jager; L Dorland; L Bruinvis; D Ketting; L Ijlst; F J van Sprang Journal: Eur J Pediatr Date: 1991-01 Impact factor: 3.183
Authors: F Rocchiccioli; R J Wanders; P Aubourg; C Vianey-Liaud; L Ijlst; M Fabre; N Cartier; P F Bougneres Journal: Pediatr Res Date: 1990-12 Impact factor: 3.756
Authors: E Bertini; C Dionisi-Vici; B Garavaglia; A B Burlina; M Sabatelli; M Rimoldi; A Bartuli; G Sabetta; S DiDonato Journal: Eur J Pediatr Date: 1992-02 Impact factor: 3.183
Authors: Melanie B Gillingham; Richard G Weleber; Martha Neuringer; William E Connor; Monte Mills; Sandy van Calcar; James Ver Hoeve; Jon Wolff; Cary O Harding Journal: Mol Genet Metab Date: 2005-07-22 Impact factor: 4.797